Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

January

17

electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update

ROCKAWAY, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage...

20

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep

Truvaga™ handheld non-invasive vagus nerve stimulator offers drug-free 2-minute sessions ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE...

7

electroCore Announces Issuance of Two New U.S. Patents

Expansion of patent portfolio allows exploration of the role of nVNS beyond migraine and...

18

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage...

3

electroCore Announces Third Quarter 2022 Financial Results

Third quarter 2022 revenue grew 33% over third quarter 2021 ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) —...

1

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

ROCKAWAY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company,...

20

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury

Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety...

14

electroCore Provides Select Third Quarter 2022 Financial Guidance

ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage...

21

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

Four patents issued expanding claims related to delivery of nVNS and other therapies using...

7

gammaCore Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder

(Non-Invasive Vagus Nerve Stimulation; nVNS) ROCKAWAY, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR),...

4

electroCore Announces Record Second Quarter 2022 Financial Results

Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and...

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021 June...

Recent developments

News

January

17

electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update

December

20

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep

December

7

electroCore Announces Issuance of Two New U.S. Patents

November

18

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

November

3

electroCore Announces Third Quarter 2022 Financial Results

November

1

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

October

20

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury

October

14

electroCore Provides Select Third Quarter 2022 Financial Guidance

September

21

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

September

7

gammaCore Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder

August

4

electroCore Announces Record Second Quarter 2022 Financial Results

July

12

electroCore Provides Select Second Quarter 2022 Financial Guidance